Home
About Us
Our Biosimilars
Biosimilars
Our Products
Newsroom
Contact Us
Contact Us
Official press releases and media coverage
2022
Hetero’s ‘NIRMACOM’ is world’s first generic version of COVID-19 oral drug ‘PAXLOVID’ to receive WHO Prequalification
Hetero acquires manufacturing plant at Penjerla in Telangana, India
Hetero unveils new logo and corporate brand identity
Hetero receives CDSCO approval to manufacture Sputnik Light vaccine for sale in India
Hetero enters into a voluntary licensing agreement with MPP to expand access of nirmatrelvir & ritonavir generics for COVID-19 treatment in 95 countries.
Hetero presents positive results from Molnupiravir Phase III Studies at CROI 2022
2021
Hetero announces approval and launch of Movfor (Molnupiravir 200 mg) to treat high-risk adult patients with COVID-19.
Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India.
Hetero’s Biosimilar Version of Tocilizumab (Tocira) receives Emergency Use Authorization (EUA) from DCGI for the treatment of Covid-19 in hospitalized adults
Hetero enters into a voluntary licensing agreement with MSD for the manufacturing and distribution of ‘Molnupiravir’, an investigational Oral Therapeutic for the treatment of Covid-19
2020
Hetero RDIF Sputnik V Vaccine
Hetero Remdesivir South Africa
Hetero Favivir India
Hetero Healthcare Covifor Supply
Hetero Covifor launch India
Hetero Licensing Gilead
Hetero Covid-19 Telangana Govt
2019
Hetero Taffic Launch Bictegravir
Hetero Lapatinib Hertab
Hetero Tarbis Farma Acquisition
2018
Hetero Tafero EM India
Hetero Adalimumab Mabura
2017
Hetero Darunavir Ritonavir India
Hetero Sofosbuvir Velpatasvir India
2016
Hetero Bevacizumab India
2015
Hetero Daclatasvir India
Hetero Ledipasvir Sofosbuvir India
Hetero Biosimilar Rituximab India
Hetero Sofovir India
2014
India, Hyderabad, 15th September 2014
Hetero Sofosbuvir Licensing agreement
×
Enquire Now
SUBMIT
